Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 6/2012

01.11.2012 | Original Article

Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series

verfasst von: Anke Thümler, Elke Miebach, Christina Lampe, Susanne Pitz, Wolfgang Kamin, Christoph Kampmann, Bianca Link, Eugen Mengel

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

To assess clinical features and general health status of adult patients with mucopolysaccharidosis (MPS) VI.

Methods

This report includes the clinical history of patients older than 18 years with slowly progressing MPS VI and the retrospective analysis of the outcomes of available data collected between September 2003 and October 2008 at the Center of Pediatric and Adolescent Medicine, University Medical Center, Johannes Gutenberg-University of Mainz, Germany. Variables included were urinary glycosaminoglycan (uGAG) level, mutation analysis, body height, forced vital capacity (FVC), 6-minute walk test, echocardiographic findings, the need for craniocervical decompression surgery, orthopaedic findings and ophthalmological assessments.

Results

The analysis included nine patients with MPS VI aged 19-29 years. The median age at diagnosis was 12 (range 6–20) years. At the time of the assessment (median age 25 years), median uGAG was 29 (range 15-149) μg/mg creatinine and median height 152 (range 136–161) cm. All patients had a FVC below standard values, seven showed reduced endurance in the 6-minute-walk test, all had valve changes with valve replacement in three, two underwent craniocervical decompression surgery, two underwent carpal tunnel surgery, five had ear/nose/throat (ENT) interventions, seven had hip pain/dysplasia, seven had corneal clouding and two were visually impaired.

Conclusions

Although patients with slowly progressing MPS VI are a heterogeneous group showing disease manifestations in several organs, they seem to have some typical characteristics in common. Despite the attenuated clinical course, many of these patients show severe morbidity. Therefore, early diagnosis and proper follow-up and treatment are essential.
Literatur
Zurück zum Zitat Ashworth JL, Biswas S, Wraith E, Lloyd IC (2006) The ocular features of the mucopolysaccharidoses. Eye 20:553–563PubMedCrossRef Ashworth JL, Biswas S, Wraith E, Lloyd IC (2006) The ocular features of the mucopolysaccharidoses. Eye 20:553–563PubMedCrossRef
Zurück zum Zitat Azevedo ACMM, Schwartz IV, Kalakun L et al (2004) Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet 66:208–213PubMedCrossRef Azevedo ACMM, Schwartz IV, Kalakun L et al (2004) Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet 66:208–213PubMedCrossRef
Zurück zum Zitat Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017PubMedCrossRef Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017PubMedCrossRef
Zurück zum Zitat Decker C, Yu Z, Giugliani R et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI: growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med 3:89–100PubMed Decker C, Yu Z, Giugliani R et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI: growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med 3:89–100PubMed
Zurück zum Zitat Enright PL, Sherrill DL (1998) Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 158:1384–1387PubMed Enright PL, Sherrill DL (1998) Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 158:1384–1387PubMed
Zurück zum Zitat Fesslová V, Corti P, Sersale G et al (2009) The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young 19:170–178PubMedCrossRef Fesslová V, Corti P, Sersale G et al (2009) The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young 19:170–178PubMedCrossRef
Zurück zum Zitat Giugliani R, Harmatz P, Wraith JE (2007) Management guidelines for mucopolysaccharidosis VI. Pediatrics 120:405–418PubMedCrossRef Giugliani R, Harmatz P, Wraith JE (2007) Management guidelines for mucopolysaccharidosis VI. Pediatrics 120:405–418PubMedCrossRef
Zurück zum Zitat Gottwald I, Hughes J, Stewart F et al (2011) Attenuated mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) due to homozygosity for the p.Y210C mutation in the ARSB gene. Mol Genet Metab 103:300–302PubMedCrossRef Gottwald I, Hughes J, Stewart F et al (2011) Attenuated mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) due to homozygosity for the p.Y210C mutation in the ARSB gene. Mol Genet Metab 103:300–302PubMedCrossRef
Zurück zum Zitat Harmatz P, Whitley CB, Waber L et al (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144:574–580PubMedCrossRef Harmatz P, Whitley CB, Waber L et al (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144:574–580PubMedCrossRef
Zurück zum Zitat Harmatz P, Ketteridge D, Giugliani R et al (2005) Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115:e681–e689PubMedCrossRef Harmatz P, Ketteridge D, Giugliani R et al (2005) Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115:e681–e689PubMedCrossRef
Zurück zum Zitat Harmatz P, Giugliani R, Schwartz I et al (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148:533–539PubMedCrossRef Harmatz P, Giugliani R, Schwartz I et al (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148:533–539PubMedCrossRef
Zurück zum Zitat Harmatz P, Yu ZF, Giugliani R et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis 33:51–60PubMedCrossRef Harmatz P, Yu ZF, Giugliani R et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis 33:51–60PubMedCrossRef
Zurück zum Zitat Hendriksz CJ, Giugliani R, Harmatz P et al (2011) Design, baseline characteristics and early findings of the MPS VI Clinical Surveillance Program (CSP). J Inherit Metab Dis. doi:10.1007/s10545-011-9410-9 Hendriksz CJ, Giugliani R, Harmatz P et al (2011) Design, baseline characteristics and early findings of the MPS VI Clinical Surveillance Program (CSP). J Inherit Metab Dis. doi:10.​1007/​s10545-011-9410-9
Zurück zum Zitat Isbrandt D, Arlt G, Brooks DA, Hopwood JJ, von Figura K, Peters C (1994) Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): six unique arylsulfatase B gene alleles causing variable disease phenotypes. Am J Hum Genet 54:454–463PubMed Isbrandt D, Arlt G, Brooks DA, Hopwood JJ, von Figura K, Peters C (1994) Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): six unique arylsulfatase B gene alleles causing variable disease phenotypes. Am J Hum Genet 54:454–463PubMed
Zurück zum Zitat Karageorgos L, Brooks DA, Pollard A et al (2007) Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat 28:897–903PubMedCrossRef Karageorgos L, Brooks DA, Pollard A et al (2007) Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat 28:897–903PubMedCrossRef
Zurück zum Zitat Leal GN, de Paula AC, Leone C, Kim CA (2010) Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol Young 20:254–261PubMedCrossRef Leal GN, de Paula AC, Leone C, Kim CA (2010) Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol Young 20:254–261PubMedCrossRef
Zurück zum Zitat Litjens T, Brooks DA, Peters C, Gibson GJ, Hopwood JJ (1996) Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Am J Hum Genet 58:1127–1134PubMed Litjens T, Brooks DA, Peters C, Gibson GJ, Hopwood JJ (1996) Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Am J Hum Genet 58:1127–1134PubMed
Zurück zum Zitat McGill JJ, Inwood AC, Coman DJ, Lipke ML et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age–a sibling control study. Clin Genet 77:492–498PubMedCrossRef McGill JJ, Inwood AC, Coman DJ, Lipke ML et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age–a sibling control study. Clin Genet 77:492–498PubMedCrossRef
Zurück zum Zitat Mut M, Cila A, Varli K, Akalan N (2005) Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature. Clin Neurol Neurosurg 107:230–235PubMedCrossRef Mut M, Cila A, Varli K, Akalan N (2005) Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature. Clin Neurol Neurosurg 107:230–235PubMedCrossRef
Zurück zum Zitat Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3421–3452 Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3421–3452
Zurück zum Zitat Scarpa M, Buffone E, La Marca P, Campello M, Rampazzo A (2010) Difficulties in diagnosing slowly progressive mucopolysaccharidosis VI: a case series. J Pediatr Rehabil Med 3:71–75PubMed Scarpa M, Buffone E, La Marca P, Campello M, Rampazzo A (2010) Difficulties in diagnosing slowly progressive mucopolysaccharidosis VI: a case series. J Pediatr Rehabil Med 3:71–75PubMed
Zurück zum Zitat Swiedler SJ, Beck M, Bajbouj M et al (2005) Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet 134A:144–150PubMedCrossRef Swiedler SJ, Beck M, Bajbouj M et al (2005) Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet 134A:144–150PubMedCrossRef
Zurück zum Zitat Thorne JA, Javadpour M, Hughes DG, Wraith E, Cowie RA (2001) Craniovertebral abnormalities in type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome). Neurosurgery 48:849–853PubMed Thorne JA, Javadpour M, Hughes DG, Wraith E, Cowie RA (2001) Craniovertebral abnormalities in type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome). Neurosurgery 48:849–853PubMed
Zurück zum Zitat Valayannopoulos V, Nicely H, Harmatz P, Turbeville S (2010) Mucopolysaccharidosis VI. Orphanet J Rare Dis 5:5PubMedCrossRef Valayannopoulos V, Nicely H, Harmatz P, Turbeville S (2010) Mucopolysaccharidosis VI. Orphanet J Rare Dis 5:5PubMedCrossRef
Zurück zum Zitat Wippermann CF, Beck M, Schranz D, Huth R, Michel-Behnke I, Jüngst BK (1995) Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr 154:98–101PubMedCrossRef Wippermann CF, Beck M, Schranz D, Huth R, Michel-Behnke I, Jüngst BK (1995) Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr 154:98–101PubMedCrossRef
Metadaten
Titel
Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series
verfasst von
Anke Thümler
Elke Miebach
Christina Lampe
Susanne Pitz
Wolfgang Kamin
Christoph Kampmann
Bianca Link
Eugen Mengel
Publikationsdatum
01.11.2012
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 6/2012
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-012-9474-1

Weitere Artikel der Ausgabe 6/2012

Journal of Inherited Metabolic Disease 6/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.